Hari Sankaran1, Heather E Danysh1, Michael E Scheurer1, M Fatih Okcu1, Stephen X Skapek2, Douglas S Hawkins3, Logan G Spector4, Erik B Erhardt5, Seymour Grufferman6, Philip J Lupo1. 1. Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas. 2. Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. 3. Seattle Children's Hospital, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, Washington. 4. Division of Pediatric Epidemiology and Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota. 5. Department of Mathematics and Statistics, University of New Mexico, Albuquerque, New Mexico. 6. Division of Epidemiology and Biostatistics, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico.
Abstract
BACKGROUND: Rhabdomyosarcoma (RMS) is a rare, highly malignant tumor arising from primitive mesenchymal cells that differentiate into skeletal muscle. Relatively little is known about RMS susceptibility. Based on growing evidence regarding the role of early immunologic challenges on RMS development, we evaluated the role of infections and immunizations on this clinically significant pediatric malignancy. PROCEDURE: RMS cases (n = 322) were enrolled from the third trial coordinated by the Intergroup Rhabdomyosarcoma Study Group. Population-based controls (n = 322) were pair matched to cases on race, sex, and age. The following immunizations were assessed: diphtheria, pertussis, and tetanus (DPT); measles, mumps, and rubella; and oral polio vaccine. We also evaluated if immunizations were complete versus incomplete. We examined selected infections including chickenpox, mumps, pneumonia, scarlet fever, rubella, rubeola, pertussis, mononucleosis, and lung infections. Conditional logistic regression models were used to calculate an odds ratio (OR) and 95% confidence interval (CI) for each exposure, adjusted for maternal education and total annual income. RESULTS: Incomplete immunization schedules (OR = 5.30, 95% CI: 2.47-11.33) and incomplete DPT immunization (OR = 1.56, 95% CI: 1.06-2.29) were positively associated with childhood RMS. However, infections did not appear to be associated with childhood RMS. CONCLUSIONS: This is the largest study of RMS to date demonstrating a possible protective effect of immunizations against the development of childhood RMS. Further studies are needed to validate our findings. Our findings add to the growing body of literature, suggesting a protective role of routine vaccinations in childhood cancer and specifically in childhood RMS.
BACKGROUND:Rhabdomyosarcoma (RMS) is a rare, highly malignant tumor arising from primitive mesenchymal cells that differentiate into skeletal muscle. Relatively little is known about RMS susceptibility. Based on growing evidence regarding the role of early immunologic challenges on RMS development, we evaluated the role of infections and immunizations on this clinically significant pediatric malignancy. PROCEDURE: RMS cases (n = 322) were enrolled from the third trial coordinated by the Intergroup Rhabdomyosarcoma Study Group. Population-based controls (n = 322) were pair matched to cases on race, sex, and age. The following immunizations were assessed: diphtheria, pertussis, and tetanus (DPT); measles, mumps, and rubella; and oral polio vaccine. We also evaluated if immunizations were complete versus incomplete. We examined selected infections including chickenpox, mumps, pneumonia, scarlet fever, rubella, rubeola, pertussis, mononucleosis, and lung infections. Conditional logistic regression models were used to calculate an odds ratio (OR) and 95% confidence interval (CI) for each exposure, adjusted for maternal education and total annual income. RESULTS: Incomplete immunization schedules (OR = 5.30, 95% CI: 2.47-11.33) and incomplete DPT immunization (OR = 1.56, 95% CI: 1.06-2.29) were positively associated with childhood RMS. However, infections did not appear to be associated with childhood RMS. CONCLUSIONS: This is the largest study of RMS to date demonstrating a possible protective effect of immunizations against the development of childhood RMS. Further studies are needed to validate our findings. Our findings add to the growing body of literature, suggesting a protective role of routine vaccinations in childhood cancer and specifically in childhood RMS.
Authors: Greta R Bunin; Logan G Spector; Andrew F Olshan; Leslie L Robison; Michelle Roesler; Seymour Grufferman; Xiao-ou Shu; Julie A Ross Journal: Am J Epidemiol Date: 2007-04-23 Impact factor: 4.897
Authors: Philip J Lupo; Renke Zhou; Stephen X Skapek; Douglas S Hawkins; Logan G Spector; Michael E Scheurer; M Fatih Okcu; Beatrice Melin; Karin Papworth; Erik B Erhardt; Seymour Grufferman Journal: Int J Cancer Date: 2013-08-01 Impact factor: 7.396
Authors: Margaret Wrensch; Adriana Weinberg; John Wiencke; Rei Miike; Jennette Sison; Joseph Wiemels; Geoffrey Barger; Gerald DeLorenze; Kenneth Aldape; Karl Kelsey Journal: Am J Epidemiol Date: 2005-05-15 Impact factor: 4.897
Authors: Seymour Grufferman; Frederick Ruymann; Simona Ognjanovic; Erik B Erhardt; Harold M Maurer Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-03-17 Impact factor: 4.254
Authors: Florence Menegaux; Andrew F Olshan; Joseph P Neglia; Brad H Pollock; Melissa L Bondy Journal: Am J Epidemiol Date: 2004-05-01 Impact factor: 4.897
Authors: Neimar de Paula Silva; Rejane de Souza Reis; Rafael Garcia Cunha; Júlio Fernando Pinto Oliveira; Marceli de Oliveira Santos; Maria S Pombo-de-Oliveira; Beatriz de Camargo Journal: PLoS One Date: 2016-10-21 Impact factor: 3.240